Related Experiment Video

Updated: Jun 16, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and

Nuggehally R Srinivas1

  • 1Suramus Biopharm, Integrated Drug Development, J.P. Nagar I phase, Bangalore 560 025, India.

European Journal of Drug Metabolism and Pharmacokinetics
|February 20, 2010
PubMed

Insights

Genetic CYP2C19 polymorphism can cause clopidogrel resistance. This study explores strategies, including induction and chemical design, to overcome these genetic hurdles for diverse patient populations.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Cardiovascular Therapeutics

Background:

  • Clopidogrel is a widely used antiplatelet medication.
  • CYP2C19 genetic variations are linked to clopidogrel treatment resistance.
  • This resistance impacts therapeutic efficacy in certain patient groups.

Purpose of the Study:

  • To propose strategies for overcoming CYP2C19-related clopidogrel resistance.
  • To address challenges in delivering effective antiplatelet therapy in diverse populations.

Main Methods:

  • Review of existing evidence on CYP2C19 polymorphism and clopidogrel response.
  • Exploration of potential therapeutic strategies: induction, chemical structure modification, and dosing adjustments.

Main Results:

  • Established evidence supports induction strategies and chemical structure design to mitigate polymorphism effects.
  • A speculative dosing input strategy is proposed as a potential avenue for further research.

Conclusions:

  • Novel approaches are crucial for personalized antiplatelet therapy.
  • Addressing genetic variations like CYP2C19 polymorphism is key for equitable and effective medicine delivery.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...